Clinical potential of oral direct thrombin inhibitors in the prevention and treatment of venous thromboembolism

Drugs

Volumn 64, Issue SUPPL. 1, 2004, Pages 47-52

  Agnelli, Giancarlo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; COUMARIN DERIVATIVE; DABIGATRAN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LIVER ENZYME; MELAGATRAN; PLASMA PROTEIN; THROMBIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HUMAN; KNEE ARTHROPLASTY; LUNG EMBOLISM; MONITORING; PARTIAL THROMBOPLASTIN TIME; PHLEBOGRAPHY; REVIEW; SECONDARY PREVENTION; STROKE; THROMBOCYTOPENIA; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; CLINICAL TRIALS; HUMANS; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; THROMBIN; VENOUS THROMBOSIS;

EID: 4644247209     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464001-00007     Document Type: Review

References (20)

1. Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: heparin: a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103: 2994-3018
2. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-711
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl.): 64S-94S
4. Hyers TM. Management of venous thromboembolism: past, present, and future. Arch Intern Med 2003; 163 (Pt 7): 759-68
5. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97 (Pt 6): 544-52
6. Clagett GP, Anderson FA Jr, Geerts W, et al. Prevention of venous thromboembolism. Chest 1998; 114 (5 Suppl.): 531S-60S
7. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001; 119 (1 Suppl): 132S-75S
8. Eriksson BI, Bergqvist D, Kalebo P, et al. Melagatran for thrombin inhibition in Oothopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360 (9344): 1441-7
9. Eriksson BI, Agnelli G, Cohen AT, et al. METHRO III Study Group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003; 89 (Pt 2): 288-96
10. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490-6
11. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137 (Pt 8): 648-55
12. Colwell CW Jr, Berkowitz D, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost 2003; 1 (Pt 10): 2119-30
13. Francis CW, Berkowitz SD, Comp PC, et al. EXULT A Study Group. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003; 349 (Pt 18): 1703-12
14. Colwell CW Jr, Berkowitz SD, Comp PC, et al. Randomized double-blind comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism (VTE) after total knee replacement (TKR): EXULT B. Blood 2003; 102 (Pt 11): abstract no. 39
15. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE 1. J Thromb Haemost 2003; 1 (Pt 1): 41-7
16. Francis CW, Ginsberg JS, Berkowitz SD, et al. Efficacy and safety of the oral direct thrombin inhibitor ximetagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: The THRIVE treatment study. Blood 2003; 102 (11 Pt 1): 6a abstract no. 7
17. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003; 349 (Pt 18): 1713-21
18. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348 (Pt 15): 1425-34
19. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349 (Pt 7): 631-9
20. Olsson SB, Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003; 362 (9397): 1691-8